Sensei Biotherapeutics (SNSE) COO and director added as SEC insider

Rhea-AI Filing Summary

Sensei Biotherapeutics, Inc. filed an initial insider ownership report for Parikh Anand Kiran. The filing identifies him as both a director and the Chief Operating Officer of the company. This Form 3 does not report any specific stock transactions or share amounts.

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Parikh Anand Kiran

(Last) (First) (Middle)

C/O SENSEI BIOTHERAPEUTICS, INC.

1405 RESEARCH BLVD, SUITE 125

(Street)

ROCKVILLE MD 20850

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
02/17/2026

3. Issuer Name and Ticker or Trading Symbol
Sensei Biotherapeutics, Inc. [ SNSE ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit 24 - Power of Attorney

No securities are beneficially owned.

	/s/ Anand Kiran Parikh	02/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does the Sensei Biotherapeutics (SNSE) Form 3 filing for Parikh Anand Kiran show?

The Form 3 filing records Parikh Anand Kiran as a director and Chief Operating Officer of Sensei Biotherapeutics. It serves as an initial insider ownership statement and does not list any stock transactions or specific share holdings.

Who is the insider named in Sensei Biotherapeutics (SNSE) latest Form 3?

The insider is Parikh Anand Kiran, who is listed as both a director and the Chief Operating Officer of Sensei Biotherapeutics. The filing simply establishes his status as a reporting person under SEC rules for insiders.

Does the SNSE Form 3 for Parikh Anand Kiran report any share transactions?

No, the Form 3 for Parikh Anand Kiran does not report any share transactions. It provides only role information, indicating he is a director and Chief Operating Officer, without detailing purchases, sales, or specific ownership amounts.

Why did Sensei Biotherapeutics (SNSE) file a Form 3 for Parikh Anand Kiran?

Sensei Biotherapeutics filed a Form 3 because Parikh Anand Kiran is an insider as a director and Chief Operating Officer. SEC rules require an initial ownership statement when someone becomes an officer or director of a public company.

What roles does Parikh Anand Kiran hold at Sensei Biotherapeutics (SNSE)?

Parikh Anand Kiran holds two roles at Sensei Biotherapeutics: he is a director and also serves as the company’s Chief Operating Officer. These positions make him a reporting person for SEC insider disclosure purposes.